Sinopharm Group Co. Ltd. — Earnings Release 2024

Mar 20, 2025

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

国药集团

SINOPHARM

國藥控股股份有限公司

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF CNMDC FOR THE YEAR ENDED 31 DECEMBER 2024

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement dated 20 March 2025 (the "Announcement") issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the annual report of China National Medical Device Co., Ltd. (中國醫療器械有限公司) ("CNMDC"), a subsidiary of the Company, for the year ended 31 December 2024 issued by CNMDC on the websites of China Money and Shanghai Clearing House.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited financial data of CNMDC for the year ended 31 December 2024 as set out in the Announcement.

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."

---

2

PRINCIPAL FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS

Unit: Yuan
Currency: RMB

	The year of 2024	The year of 2023	Changes of this year compared with last year
Revenue	76,698,316,757.24	83,141,839,433.98	-7.75%
Operating profit	1,219,453,089.52	2,595,876,738.91	-53.02%
Total comprehensive income attributable to owners of the parent company	403,336,362.93	1,031,123,119.09	-60.88%
Net cash flow arising from operating activities	-1,356,284,840.11	732,098,258.50	-285.26%
	As at 31 December 2024	As at 31 December 2023	Changes of 2024 year-end over 2023 year-end
Total assets	61,661,013,678.38	57,791,918,661.02	6.69%
Total equity attributable to owners of the parent company	7,884,395,529.18	7,716,613,619.48	2.17%

By order of the Board
Sinopharm Group Co. Ltd.
Zhao Bingxiang
Chairman

Shanghai, the PRC
20 March 2025

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Sun Jinglin; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Hu Ligang, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.